GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

A Comparison of the Haemodynamic and Metabolic Effects of Intravenous Glucagon-like Peptide-1, Glucagon and Glucagon-like Peptide-1:Glucagon Co-agonism in Healthy Male Participants
NCT03835013 on ClinicalTrials.gov

Status
CompletedResults none
Why it is watched
non-weight indication: cardiovascular
Who it enrolls
age 18 Years to 40 Years; male; healthy volunteers accepted; excludes diabetes; BMI ≥18 required; non-obese participants included; conditions: Cardiovascular Diseases
Interventions
Saline 0.9%; Glucagon (25ng/kg/min); Glucagon (50ng/kg/min); Exenatide
Conditions
Cardiovascular Diseases
Phase and size
NA · 26 participants
Dates
Start 2019-02-11
Primary completion 2021-11-01
Sponsor
Cambridge University Hospitals NHS Foundation Trust (Other)
Last checked
Sep 13, 2026
01Endpoints

What the trial will measure

  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
  • Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.Comparison between 2 hour infusion visit 1-2 (Part A) / 1 hour infusion visit 1-4 (Part B), over a maximum period of 15 weeks
02Eligibility

Who can take part

Inclusion Criteria: * Written informed consent to participate * Aged 18 to 40 * Male * Current non-smoker * BMI \>18.0 and \<30kg/m2 Exclusion Criteria: * Female * Sustained Hypertension (sustained BP \>160/100mmHg) or hypotension (systolic BP below 90 mmHg) * Clinically significant heart disease * Implanted heart pace-maker or implantable cardioverter defibrillator (ICD) * Known active malignancy * Known renal failure (creatinine \>140μmol/L) * Known diabetes mellitus (type 1 or 2) * Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits * Use of formal anticoagulant therapy such as, but not limited to, heparin, warfarin or rivaroxaban * Current involvement in the active treatment phase of other research studies, (excluding observations/noninterventional) * Any other clinical reason which may preclude entry in the opinion of the investigator
03Change log

Registry changes

No changes recorded since the trial was added.